Seven Grand Managers’s Bicara Therapeutics BCAX Stock Holding History

Seven Grand Managers’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86M	Hold	62,500	–	–	0.07%	144
2026 Q1	$1.24M	Buy	+62,500	New	+$1.08M	0.08%	142

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Seven Grand Managers's BCAX Position: Q2 2026 in Review

Seven Grand Managers held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 62,500 shares worth $1.86M. The position accounts for 0.07% of the portfolio, ranked #144.

Seven Grand Managers first reported a position in BCAX in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

Seven Grand Managers held 62,500 shares of Bicara Therapeutics worth $1.86M as of Q2 2026.
Seven Grand Managers left its Bicara Therapeutics share count unchanged in Q2 2026.
Bicara Therapeutics made up 0.07% of Seven Grand Managers's portfolio in Q2 2026, its #144 holding.
Seven Grand Managers first reported a position in Bicara Therapeutics in Q1 2026 and has held it in 2 quarters since.
172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.